MENLO PARK, Calif.--()--Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today that the company has been named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies for 2012.
“Nevro has developed an innovative approach to pain management with the Senza™ High-Frequency Spinal Cord Stimulation System, which shows early potential to deliver relief for patients with difficult-to-treat chronic pain”
FierceMedicalDevices editors chose this year's winners based on their management teams, notable financial backing, promising technologies and market opportunities. The award was announced today at an event that took place during AdvaMed 2012: The MedTech Conference in Boston, Massachusetts.
“Nevro has developed an innovative approach to pain management with the Senza™ High-Frequency Spinal Cord Stimulation System, which shows early potential to deliver relief for patients with difficult-to-treat chronic pain,” said FierceMedicalDevices Editor Damian Garde.
Nevro’s Senza System delivers electrical pulses to the spinal cord to reduce the transmission of pain signals to the brain. The electrical pulses are delivered by small electrodes that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin. Early data from European clinical studies suggest that high-frequency spinal cord stimulation may offer the ability to treat low back pain and other challenging conditions that often do not respond to conventional therapy, and may treat such conditions without triggering the tingling sensation known as paresthesia that is typically associated with traditional SCS systems.
The Senza System is presently the subject of the SENZA-RCT study, a prospective, randomized, controlled pivotal study intended to evaluate the safety and efficacy of Nevro’s Senza High-Frequency Spinal Cord Stimulation System in patients with chronic pain. The study will enroll approximately 300 patients at 15 leading pain centers across the U.S. The Senza System is authorized for sale in Europe and Australia. In the United States, the system is limited by federal law to investigational use and is not available for sale.
An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations, and post-marketing. A complete list of "Fierce 15" companies is available online at www.fiercemedicaldevices.com.
About Nevro Corp.
Privately held Nevro Corp., headquartered in Menlo Park, Calif., is focused on the development and commercialization of high-frequency spinal cord stimulation for chronic pain. Nevro’s investors include Johnson & Johnson Development Corporation, Bay City Capital, Three Arch Partners, Aberdare Ventures, MPM Capital and Accuitive Medical Ventures. For more information visit www.nevro.com.
Senza, Nevro and the Nevro logo are trademarks of Nevro Corp.
Caution – Investigational device, limited by Federal (or United States) law to investigational use.